Voyager Therapeutics Business Summary

Voyager Therapeutics, Inc. (VYGR) operates as a clinical-stage biotechnology firm specializing in neurogenetic medicines, generating revenue through a hybrid model of licensing fees, milestone payments, and R&D reimbursements from high-tier pharmaceutical collaborations. The company’s primary business segments revolve around its proprietary TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) platform, which discovers novel AAV capsids for central nervous system (CNS) delivery, and its internal pipeline targeting Alzheimer’s disease, ALS, and Parkinson’s. Voyager’s financial stability is anchored by multi-billion dollar partnership agreements with Neurocrine Biosciences, Novartis, and Alexion (AstraZeneca), focusing on blood-brain barrier (BBB) penetration. In a competitive field featuring REGENXBIO, Spark Therapeutics, and Alector, Voyager maintains a distinct market position as a specialized platform provider and drug developer whose engineered capsids offer superior CNS tropism and lower systemic toxicity compared to first-generation AAV vectors. Voyager was co-founded in 2013 by a pedigree team of gene therapy and neuroscience experts, including Steven M. Paul, M.D. (former Lilly executive), Guangping Gao, Ph.D., Mark Kay, M.D., Ph.D., and Phillip Zamore, Ph.D. The current leadership is led by President and CEO Alfred "Al" Sandrock, M.D., Ph.D., the former R&D chief at Biogen credited with bringing multiple blockbuster neuro-therapies to market. Supporting Sandrock are Chief Scientific Officer Todd Carter, Ph.D., Chief Medical Officer Toby Ferguson, M.D., Ph.D., and Chief Financial Officer Nathan Jorgensen, Ph.D., alongside Robin Swartz serving as Chief Business and Operating Officer. The company is supported by a robust board chaired by Michael Higgins and maintains strong institutional backing from founding investor Third Rock Ventures, as well as PFM Health Sciences and Wellington Management, ensuring a strategic focus on transforming the treatment of complex neurological disorders.